Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.

JCO precision oncology - 1 Jan 2023

Coleman Niamh, Marcelo Kathrina L, Hopkins Julia F, Khan Nusrat Israr, Du Robyn, Hong Lingzhi, Park Edward, Balsara Binaifer, Leoni Mollie, Pickering Curtis, Myers Jeffrey, Heymach John, Albacker Lee A, Hong David, Gillison Maura, Le Xiuning

Abstract excerpt

PURPOSE: In head and neck squamous cell carcinoma (HNSCC), HRAS mutation is a new actionable oncogene driver. We aimed to evaluate HRAS mutational variants, comutation profile, and survival outcomes of this molecularly defined population. METHODS: We leveraged four deidentified patient data sets with HRAS-mutant HNSCC, MD Anderson Cancer Center, Kura Oncology, Inc trial, Foundation Medicine, and American...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Head and Neck Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins p21(ras)

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 36603172
DOI: 10.1200/PO.22.00211
PMCID: PMC9928766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.PMID 36603172Read ↗

Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.Semantic proximity Read ↗

Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Semantic proximity Read ↗

Molecular landscape of head and neck cancer and implications for therapySemantic proximity Read ↗

Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.Semantic proximity Read ↗

Tumor Subtype Classification Tool for HPV-associated Head and Neck CancersSemantic proximity Read ↗

Sequencing the head and neck cancer genome: implications for therapy.Semantic proximity Read ↗

The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinomaSemantic proximity Read ↗

Novel insight into mutational landscape of head and neck squamous cell carcinoma.Semantic proximity Read ↗

Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis.Semantic proximity Read ↗

Hallmarks of a Genomically Distinct Subclass of Head and Neck CancerSemantic proximity Read ↗

Hallmarks of a genomically distinct subclass of head and neck cancer.Semantic proximity Read ↗

The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.